Center for Human Genetics, KU Leuven, Belgium.
Center for Cancer Biology, VIB, Leuven, Belgium.
Haematologica. 2017 Sep;102(9):1605-1616. doi: 10.3324/haematol.2016.146571. Epub 2017 Jun 28.
Anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma is characterized by 2p23/ aberrations, including the classic t(2;5)(p23;q35)/ rearrangement present in ~80% of cases and several variant t(2p23/ALK) occurring in the remaining cases. The fusion partners play a key role in the constitutive activation of the chimeric protein and its subcellular localization. Using various molecular technologies, we have characterized ALK fusions in eight recently diagnosed anaplastic large cell lymphoma cases with cytoplasmic-only ALK expression. The identified partner genes included (one case), (one case), (four cases) and (two cases). Notably, all cases showed copy number gain of the rearranged gene, which is never observed in -positive lymphomas. We hypothesized that this could be due to lower expression levels and/or lower oncogenic potential of the variant fusions. Indeed, all partner genes, except , showed lower expression in normal and malignant T cells, in comparison with In addition, we investigated the transformation potential of endogenous Npm1-Alk and Atic-Alk fusions generated by clustered regularly interspaced short palindromic repeats/Cas9 genome editing in Ba/F3 cells. We found that Npm1-Alk has a stronger transformation potential than Atic-Alk, and we observed a subclonal gain of after a longer culture period, which was not observed for Taken together, our data illustrate that lymphomas driven by the variant ATIC-ALK fusion (and likely by RNF213-ALK and TPM3-ALK), but not the classic NPM1-ALK, require an increased dosage of the hybrid gene to compensate for the relatively low and insufficient expression and signaling properties of the chimeric gene.
间变性大细胞淋巴瘤中存在间变性淋巴瘤激酶(ALK)阳性,其特征是 2p23/异常,包括经典的 t(2;5)(p23;q35)/重排,约 80%的病例存在该重排,其余病例存在几种变体 t(2p23/ALK)。融合伙伴在嵌合蛋白的组成性激活及其亚细胞定位中起着关键作用。使用各种分子技术,我们对 8 例新近诊断的具有仅细胞质 ALK 表达的间变性大细胞淋巴瘤病例中的 ALK 融合进行了特征描述。鉴定的融合伙伴基因包括 CLTC(1 例)、SEPT9(1 例)、TPM3(4 例)和 ATIC(2 例)。值得注意的是,所有病例均显示重排基因的拷贝数增加,而这在 ALK 阳性淋巴瘤中从未观察到。我们假设这可能是由于变体融合的表达水平较低和/或致瘤潜能较低。事实上,除了外,所有伙伴基因在正常和恶性 T 细胞中的表达均低于,此外,我们还研究了通过聚类规则间隔短回文重复序列/Cas9 基因组编辑生成的内源性 Npm1-Alk 和 Atic-Alk 融合在 Ba/F3 细胞中的转化潜能。我们发现 Npm1-Alk 的转化潜能强于 Atic-Alk,并且在较长的培养期后观察到的获得,而对于未观察到。综上所述,我们的数据表明,由变体 ATIC-ALK 融合(可能还有 RNF213-ALK 和 TPM3-ALK)驱动的淋巴瘤,但不是经典的 NPM1-ALK,需要增加 杂交基因的剂量,以补偿嵌合基因相对较低和不足的表达和信号特性。